MDS Labs® Develops NEUROmergence®, Specifically Targeting Adverse Kinase Enzymes, to Support Anti-aging and Cognitive Rebuilding

Key Points:

• Senolytic and senomorphic therapies are at the cutting edge of aging research, targeting and eliminating senescent cells and suppressing adverse pathways to potentially slow the aging process and improve tissue regeneration.
• The D + Q treatment, combining Dasatinib and Quercetin, has shown promising results in reducing age-related physiological declines and may help treat Long-Covid neurological symptoms.
• Building on research in natural tyrosine kinase inhibitors, NEUROmergence® has been developed to target a broad spectrum of aging and disease-related pathways. It is offered as a phytochemical-based alternative to the D + Q treatment, that benefits from enhanced tolerability and effectiveness.
• MDS Labs® plans to release NEUROmergence® later this year, offering a potentially industry-changing supplement that supports healthy aging, with prospects for personalized supplementation based on individual needs.

Valencia, CA – Senotherapeutic treatment is a rapidly emerging approach in the field of aging research and regenerative medicine. As we age, our bodies face a decline in immune system efficiency, leading to the accumulation of senescent cells. These cells impair the function of healthy cells, affecting our resilience to stress and illness, recovery from injuries, and even cognitive abilities. This cellular deterioration is a key contributor to numerous age-related diseases, including but not limited to cancer, diabetes, osteoporosis, cardiovascular diseases, strokes, Alzheimer’s and related dementias, and osteoarthritis. Senolytic treatments offer a promising solution by targeting and eliminating senescent cells, thereby fostering tissue regeneration and potentially decelerating the aging process and its associated diseases.

The D + Q treatment combines Dasatinib, a tyrosine kinase inhibitor, with Quercetin, a potent antioxidant flavonoid with neuroprotective qualities, leveraging their synergistic effects. Dasatinib induces apoptosis (cell death) in senescent cells by inhibiting the Src tyrosine kinase, while Quercetin does so by inhibiting the anti-apoptotic protein Bcl-xL (the “Philadelphia chromosome”).

Initially demonstrated to mitigate age-related physical dysfunction in mice, this groundbreaking combination has propelled a wave of human clinical trials. A notable study revealed that treatment with with D + Q significantly reduced age-related physiological declines in the human brain, and it was determined that the combination can offer therapeutic potential for COVID-19 related neurological complications, marking a significant advancement in managing Long-Covid symptoms. The treatment is also showing promise in moderating the progression of Alzheimer’s disease.

A 2020 research finding demonstrated that isolated natural compounds, at a specific dose, could also act as tyrosine kinase inhibitors, targeting these specific pathways associated with aging and disease. This concept evolved into an expansive project to test various combinations of natural compounds for potential use in the development of a phytochemical counterpart to the D + Q treatment. This new research ultimately led to the creation of NEUROmergence®. Positioned as a natural supplement to support the inhibition of enzymes targeted by D + Q, NEUROmergence® was formulated to specifically support inhibition of BCR-Abl, SRC Family (SRC, FYN, LYN), c-kit (PI3K, AKT, JAK2, STAT3, MAPK), CSF1R, PDGFRβ, BCL-2, and CDK2 pathways, while also supporting activation of AMPK.

NEUROmergence® also includes 500mg of Quercetin to fully align the supplement as a counterpart to D + Q. The product has been praised as a safer alternative due to it’s enhanced tolerability and lack of side effects. This new and innovative formulation offers consumers the opportunity to experience an anti-aging product unlike anything else on the market today. The product is anticipated to launch later this year. Click here for more information.

MDS Labs® is a Reventek® Brand.

For more information about this, or other Reventek® products, please reach out to info@reventek.com